FDMT
NASDAQ4D Molecular Therapeutics Inc.
Price$10.98+1.33 (+13.72%)
2026-04-142026-07-17
News · 26 weeks57-38%
2026-01-252026-07-19
Mix3490d
- Other13(38%)
- Insider12(35%)
- SEC Filings8(24%)
- Leadership1(3%)
Latest news
25 items- PR4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationAfter a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular d
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into emplo
- INSIDEROfficer Kirn David sold $737,410 worth of shares (58,333 units at $12.64) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 884,152 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERChief Legal Officer Bizily Scott sold $91,924 worth of shares (6,566 units at $14.00) as part of a pre-agreed trading plan and exercised 6,566 shares at a strike of $6.20 (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina SpecialistsEMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026. ASRS 2026 Presentation Details: Title:2-Year Follow Up: PRISM Phase 2b Clinical Trial EvaluatingInvestigational 4D-150, an Intravitreal Gene Therapy, in aBroad Neovascular AMD PopulationDate/Time:Saturda
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- PR4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalEMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE:HTGC) ("Hercules") for up to $200 million. "Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital
- PR4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest from investigators and patients 4FRONT-2 52-week topline data is expected in H2 2027 EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT, or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in o
- PRVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean BakerALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. "We are pleased to welcome August Moretti to our board at this transformative stage for Vivani," said Gregg Williams, Chairman of the Board. "His expertise will be instrumental as we advance our lead semaglutide implant, NPM-139, through clinical-stage development and continue to leverage our propriet
- INSIDERChief Legal Officer Bizily Scott exercised 9,810 shares at a strike of $4.14 and sold $117,720 worth of shares (9,810 units at $12.00) (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDEROfficer Kirn David sold $1,200,851 worth of shares (114,746 units at $10.47) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 942,485 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- SEC4D Molecular Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
- INSIDERSEC Form 4 filed by Director Tomasello Shawn4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Theuer Charles4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Miller-Rich Nancy4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Gray Susannah4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Milligan John F4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Sblendorio Glenn4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- INSIDERSEC Form 4 filed by Director Chacko Jacob4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company's board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into empl
- INSIDEROfficer Kirn David sold $19,258 worth of shares (1,922 units at $10.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 1,057,231 units (SEC Form 4)4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
- PR4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in June. Jefferies Global Healthcare Conference Presentation Date:Wednesday, June 3, 2026Presentation Time:3:10 p.m. ET Goldman Sachs 47th Annual Global Healthcare Conference Presentation Date:Tuesday, June 9, 2026Presentation Time:2:00 p.m. ET Archived copies of the webca
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
- PR4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 12, 2026, the compensation committee of the Company's board of directors granted 14 new non-executive employees 141,100 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employm
FDMT FAQ
7 questionsWhat does 4D Molecular Therapeutics Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment...Where does FDMT stock trade?
4D Molecular Therapeutics Inc. (FDMT) is listed on NASDAQ.What sector and industry is FDMT in?
4D Molecular Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did 4D Molecular Therapeutics Inc. go public?
4D Molecular Therapeutics Inc. (FDMT) completed its IPO in 2020.What are analysts saying about FDMT?
4D Molecular Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3300.00 price target on 2026-01-28.What companies are similar to FDMT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare FDMT side-by-side with any of them on Quantisnow.How can I track FDMT on Quantisnow?
Quantisnow aggregates 4D Molecular Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FDMT to receive live email and push alerts on every new disclosure.